Quantifying the response to antiepileptic drugs: Effect of past treatment history

Neurology

Volumn 70, Issue 1, 2008, Pages 54-65

  Schiller, Yitzhak ^a   Najjar, Yussef ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYOCLONUS SEIZURE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEIZURE; SIMPLE PARTIAL SEIZURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 37849053121     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000286959.22040.6e     Document Type: Article

References (37)

1. Browne TR, Holmes GL. Epilepsy. N Engl J Med 2001;344:1145-1151.
2. Duncan JS, Sander JW, Sisodiya SM, et al. Adult epilepsy. Lancet 2006;367:1087-1100.
3. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334:168-175.
4. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol 2004;3:729-735.
5. Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy. Neurology 2005;64 Suppl 3:S2-S11.
6. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-737.
7. Cockerell OC, Johnson AL, Sander JW, et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346:140-144.
8. Mattson RH, Cramer JA, Collins JF. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology 1996;47:68-76.
9. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34:109-122.
10. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002;11:77-84.
11. Elger CE. Pharmacoresistance: modern concept and basic data derived from human brain tissue. Epilepsia 2003;44 Suppl 5:15.
12. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiological and clinical mechanisms. Epilepsia 2005;46:858-877.
13. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006;13:277-282.
14. Nashef L, Fish DR, Sander JW, et al. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 1995;58:462-464.
15. Sillanpaa M, Jalava M, Shinnar S. Epilepsy syndromes in patients with childhood-onset seizures in Finland. Pediatr Neurol 1999;21:533-537.
16. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004;9:98-101.
17. Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999;46:45-50.
18. Camfield PR, Camfield CS, Gordon K, et al. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J Pediatr 1997;131:821-824.
19. MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48:833-841.
20. Dlugos DJ, Sammel MD, Strom BL, et al. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001;57:2259-2264.
21. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-1262.
22. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
23. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
24. Wiebe S, Blume WT, Girvin JP, et al. Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001;345:311-318.
25. Perrucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998;10:171-179.
26. Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003;60:186-190.
27. Schmidt D, Richter K. Alternative single anticonvulsant drug therapy for refractory epilepsy. Ann Neurol 1986;19:85-87.
28. Anand K, Hauser AW, Callaghan BC, et al. Long-term prognosis of refractory epilepsy in adults. Epilepsia 2004;45 suppl 7:255.
29. Sillanpaa M, Jalava M, Kaleva O, et al. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998;338:1715-1722.
30. Camfield C, Camfield P, Gordon K, et al. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 1996;46:41-44.
31. Kim WJ, Park SC, Lee SJ, et al. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999;40:290-293.
32. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001;42:357-362.
33. Kumlien E, Doss RC, Gates JR. Treatment outcome in patients with mesial temporal sclerosis. Seizure 2002;11:413-417.
34. French JA, Kanner AM, Bautista J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
35. Shorvon SD. The temporal aspects of prognosis in epilepsy. J Neurol Neurosurg Psychiatry 1984;47:1157-1165.
36. Boggs JG, Nowack WJ, Drinkard CR. Analysis of the "honey moon effect" in adult epilepsy patients. Epilepsia 2000;41(suppl 7):222.
37. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62:375-381.